Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Portugal / NCT06768736
Starting soon Not applicable

Early Warning System for Allergic Rhinitis in the MASK-air® App

NCT06768736 · tracked via the Priya Life Science Portugal tracker
Sponsor
Universidade do Porto
Phase
Not applicable
Started
2025-01-30
Last updated
2025-02-06

Condition(s) studied

Allergic Rhinitis

Investigational drug(s) / intervention(s)

Personalised early warning system

Personalised early warning system: Early warning system personalised forecasting messages

Study summary

The primary objective consists in the comparison of the combined symptom medication score values between (i) patients randomised to the early warning system personalised forecasting messages, and (ii) patients randomised to generic messages already delivered by MASK-air®.

The combined symptom medication score has recently been developed in a data-driven way and validated (https://eaaci.org/images/CSMS.pdf); it assesses allergic rhinitis control taking into account both reported symptoms and medication use.

As secondary objectives, visual analogue scales on allergic rhinitis symptoms (VAS global, nasal, eye, asthma), and medication use will also be separately compared.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: \- Adult patients (≥18 years old) of both sexes with clinical diagnosis of allergic rhinitis according to ARIA associated with pollen allergy. Exclusion Criteria: * Illiterate patients * Patients without smartphone * Patients who are not able to complete a daily monitoring questionnaire on allergic rhinitis.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Faculty of Medicine University of Porto Porto Portugal

More Universidade do Porto trials in Portugal

E-Mergir: A Digital Psychosexual Intervention for the Promotion of Mental and Sexual Health of Prostate Cancer Survivors Recruiting
Immediate Restoration of a New Implant With High Primary Stability Starting soon
Exercise Impact in Elderly With Multimorbidity: HbA1c and Blood Pressure Active, not recruiting
Efficacy of Tirzepatide for Weight Management in Patients With Suboptimal Weight Loss After Bariatric Surgery: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial Starting soon
Screening Coronary Artery Disease Using artiFicial intelligencE in Non-contrast Computed Tomography Starting soon
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06768736 on ClinicalTrials.gov ↗ ← All trials in Portugal